A number of research firms have changed their ratings and price targets for Fresenius Medical Care Corporation (NYSE: FMS):

  • 8/8/2017 – Fresenius Medical Care Corporation had its “neutral” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a price target on the stock.
  • 8/7/2017 – Fresenius Medical Care Corporation had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 8/1/2017 – Fresenius Medical Care Corporation had its “neutral” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 7/31/2017 – Fresenius Medical Care Corporation was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/24/2017 – Fresenius Medical Care Corporation was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 7/11/2017 – Fresenius Medical Care Corporation was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $54.00 price target on the stock. According to Zacks, “Fresenius Medical Care has set up a strong long term objective called the ‘Growth Strategy 2020’, where it aims to increase its revenue to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. Fresenius Medical Care reported a solid first quarter of 2017, beating the Zacks Consensus Estimate for both top line and bottom line. Furthermore, an upbeat guidance instills our confidence on the company’s stock. A wide range of dialysis products, deliberate initiatives for attaining market traction, solid international foothold, strategic acquisitions & divestments are major growth catalysts for the company at the moment. However, Fresenius Medical Care stock looks overvalued at the moment. Apart from this, the company has had a disappointing run on the bourse over the last one year. A tough regulatory environment, difficulties in attaining a solid profit margin in foreign legal-paradigms & competition in the niche markets are headwinds.”
  • 7/5/2017 – Fresenius Medical Care Corporation had its “hold” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $44.00 price target on the stock.
  • 7/4/2017 – Fresenius Medical Care Corporation had its “sell” rating reaffirmed by analysts at UBS AG.
  • 6/28/2017 – Fresenius Medical Care Corporation had its “buy” rating reaffirmed by analysts at Nord/LB.

Fresenius Medical Care Corporation (NYSE:FMS) traded down 1.64% during mid-day trading on Thursday, reaching $44.95. The company had a trading volume of 179,980 shares. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The stock has a market capitalization of $27.59 billion, a price-to-earnings ratio of 19.63 and a beta of 0.47. The company’s 50 day moving average is $47.87 and its 200 day moving average is $44.72.

Fresenius Medical Care Corporation (NYSE:FMS) last announced its earnings results on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.53 by $0.05. The business had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.96 earnings per share. Equities analysts predict that Fresenius Medical Care Corporation will post $2.76 earnings per share for the current year.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.